Serina Therapeutics, Inc. has secured up to $20 million in funding to support Phase 1b clinical trials for advanced Parkinson’s treatment. The funding, led by Serina Board Director Greg Bailey, MD, includes warrants for additional proceeds. The financing structure allows for flexibility and potential access to more funding options. The company plans to submit a U.S. IND application in Q4 2025 and begin patient dosing in Australia. The registrational study for SER-252 will evaluate safety, tolerability, and pharmacokinetics in Parkinson’s patients. The investigational therapy, SER-252, aims to provide continuous dopaminergic stimulation through subcutaneous injections.

The financing agreement with Serina Therapeutics will provide up to $20 million in funding for Phase 1b clinical trials of SER-252, an investigational therapy for advanced Parkinson’s disease. Led by Serina Board Director Greg Bailey, MD, the financing includes warrants that could result in additional proceeds. The structure allows for flexible deployment of capital and potential access to more funding options. The company plans to submit a U.S. IND application in Q4 2025 and start patient dosing in Australia. The registrational study for SER-252 will assess safety, tolerability, and pharmacokinetics in Parkinson’s patients, aiming to provide continuous dopaminergic stimulation through subcutaneous injections.

Read more at GlobeNewswire: Serina Therapeutics Secures Up to $20 Million to Advance